Page 201 - 2020_07-Haematologica-web

Lenalidomide-based regimens in elderly MM
AB
CD
EF
Figure 4. Post-hoc analysis according to frailty status in patients treated with different maintenance treatments. (A, B) Progression-free survival (PFS) (A) and over- all survival (OS) (B) in fit patients according to treatment arm. (C, D) PFS (C) and OS (D) in intermediate-fit patients according to treatment arm. (E, F) PFS (E) and OS (F) in frail patients according to treatment arm. All time to events were calculated from the time of random assignment to maintenance treatment arms (_m). R: lenalidomide; RP: lenalidomide-prednisone; PFS_m: progression-free survival from the random assignment to maintenance treatment arms; OS_m: overall survival from the random assignment to maintenance treatment arms; HR: hazard ratio; CI: confidence interval; P: P value.
haematologica | 2020; 105(7)
1943